We analyzed two cohorts of breast cancer patients: the first cohort included 18 patients with M1 status with a predominance of luminal B HER2- (in 38.8%), T4 (44.4%) patients, with lymph node involvement in 72% of patients (Table 1). Here, ERBB2 is linked to breast carcinoma.